Q3 2025 Rhythm Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Rhythm Pharmaceuticals Inc (RYTM) reported strong growth in Q3 2025, with global revenue reaching $51.3 million, a 6% sequential increase.
- The company successfully raised $189 million through an equity offering, strengthening its balance sheet and providing at least 24 months of financial runway.
- Regulatory progress was made with both the FDA and EMEA accepting filings for hypothalamic obesity (HO), keeping the company on track for a potential approval in December 2025.
- The company is preparing for the launch of its acquired hypothalamic obesity treatment, leveraging its existing commercial infrastructure and experience from the BBS launch.
- International expansion continues with MCIVRI now available in over 25 countries, and new reimbursement agreements reached in France for BBS and POMC-LiPAR deficiencies.
- The company faces challenges in diagnosing and educating about acquired hypothalamic obesity, which may impact the speed of patient identification and treatment initiation.
- There is uncertainty around the Prader-Willi syndrome trial, with a 50-50 chance of success and potential delays in making a go/no-go decision for Phase 3.
- International revenue decreased by $3.4 million quarter-over-quarter, partly due to variability in ordering patterns for name-patient sales.
- The company recorded a one-time $3.2 million charge related to French reimbursement agreements, impacting financial results.
- SG&A expenses increased by 14% sequentially, driven by costs associated with the upcoming launch in acquired hypothalamic obesity, which could pressure margins.
Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Q3 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Connolly, Investor Relations at Rhythm. Please go ahead.
Thank you, Heidi. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, Our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com. This morning, we issued a press release that provides our Q3 financial results and a business update, and that press release is also available on our website. Our agenda is listed on slide two. On the call today are David Meeker, our Chairman, Chief Executive Officer, and President; Jennifer Lee, Executive Vice President, Head of North America, Hunter Smith, Chief Financial Officer; and Yann Mazebro, Executive
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
